1.1Primary thymic tissue graft
The graft retains native thymic epithelium and stromal cells. Human hematopoietic progenitors enter the graft and develop into T cells within that tissue.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The graft retains native thymic epithelium and stromal cells. Human hematopoietic progenitors enter the graft and develop into T cells within that tissue.
A human tumor slice sits on a porous culture insert. T cells recovered from the mouse enter the culture, where fluorescence imaging measures tumor-cell death.
HLA typing identifies the differences between the two graft sources. An unstimulated group and a treatment group carry the same donor pairing, and the assay compares T-cell infiltration and tissue injury between the groups.
Human thymic epithelial cells provide HLA signals during T-cell selection. The human test tissue presents peptides on shared HLA molecules, and the assay measures T-cell activation within that graft.
Mature T cells isolated from donor blood enter the circulation of a recipient carrying the donor's tissue graft. The assay measures graft infiltration and T-cell activation over a defined observation period.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A mouse carries a human stem-cell-derived thymic organoid and a full-thickness human skin graft from the same donor or from HLA-matched donors. The mouse expresses the human leukocyte antigen (HLA) alleles used to match the thymic organoid. A removable patch holds a candidate wearable sensor material against the human skin graft, and a matched control mouse receives a patch with the backing alone. Histology measures epidermal injury and human T-cell infiltration beneath each patch.
A reconstructed skin sheet replaces an intact donor skin explant as the human tissue graft. Human dermal fibroblasts populate a collagen matrix, and human keratinocytes form a stratified epidermis on its surface at an air–liquid interface. The skin cells and the stem cells used to make the thymic organoid come from the same donor or from HLA-matched donors. The skin sheet sits epidermis-side up on a dorsal graft bed, and the HLA-matched mouse carries the thymic organoid at a separate site.
One cohort receives one stem-cell-derived thymic organoid under the left renal capsule, and a second cohort receives two organoids, one under each renal capsule. Organoids come from the same production batch and have comparable sizes at implantation. Each HLA-matched mouse also carries one human skin graft from the organoid stem-cell donor or an HLA-matched donor. Blood collected at 4, 8, and 12 weeks after implantation provides human T-cell counts for comparison between cohorts.
An HLA-matched mouse carries a stem-cell-derived thymic organoid and a dorsal human skin graft from the same donor or from HLA-matched donors. A laser speckle contrast imaging system records the skin graft and a strip of neighboring mouse skin in the same field of view. The camera uses a fixed working distance, and the imaging stage maintains a consistent surface temperature across sessions. Software calculates the ratio of graft perfusion to neighboring skin perfusion and tracks it over time.
An HLA-matched mouse carries a human stem-cell-derived thymic organoid and a skin graft from the same donor or from HLA-matched donors. A receptor sequencing workflow processes human T cells collected from serial blood samples and from the skin graft at the study endpoint. Each sample receives a molecular index that identifies the mouse, tissue, and collection time. Software groups reads by T-cell receptor beta-chain sequence and reports which groups appear in both blood and graft and how their blood frequencies change over time.
An HLA-matched mouse carries a human stem-cell-derived thymic organoid and a skin graft sourced from the same donor or from HLA-matched donors. Skin graft sections receive a nuclear stain and fluorescent labels for human CD3 and epidermal keratins. Image analysis software segments nuclei, assigns CD3 signal to individual cells, and uses the keratin signal to separate epidermis from dermis. The software reports human CD3-positive cells per square millimeter in each compartment and flags fields with poor focus or saturated signal for review.
Human induced pluripotent stem cell derivatives form a three-dimensional aggregate containing thymic epithelial cells. The aggregate sits in a pocket beneath the renal capsule, where nearby vessels supply the graft.
A small fragment of human tumor sits in a subcutaneous pocket on the flank. The fragment contains tumor cells and associated stroma, and serial caliper measurements track graft growth.
Reprogrammed blood cells from one donor supply the stem cells for the thymic organoid, and a biopsy from the same donor supplies the tissue graft. HLA genotyping identifies shared class I and class II alleles for selection of a recipient mouse that expresses those human alleles.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
For human engraftment detection, the iPS—HSC's can be labeled using a lentiviral system along with green fluorescent protein (GFP) as a reporter.A · US 2013/0273655 A1 · ¶ 51
FIGS. 2A-2D concern generation of human HSC-engineered iNKT cells in a BLT (human bone marrow-liver-thymus engrafted NOD/SCID/γc−/− mice) humanized mouse model.B · US 2021/0123022 A1 · ¶ 50
Tissues derived from iPSCs will be a nearly identical match to the cell donor and thus probably avoid rejection by the immune system.A · US 2013/0273655 A1 · ¶ 16
An empty cell means only that no passage was reproduced there.
The present invention provides for increased transplantation success by enhancing the ability of HSC to engraft in the host's hematopoietic niche through increasing, or inhibiting specific microRNAs.A · US 2013/0273655 A1 · ¶ 3
Also, the present invention is not limited to the hematopoietic stem cell niche (iPS-derived HSCs, cord blood and bone marrow stem cells), and can be extended to a variety of other tissue stem cell niches (e.g., neuronal, pancreatic) to study cellular development and differentiation for future iPS-based cellular therapies.A · US 2013/0273655 A1 · ¶ 3
Such an approach is costly, manufacture labor intensive, and difficult to broadly deliver to all patients in need.B · US 2021/0123022 A1 · ¶ 4
The ability to manufacture a therapeutic cell population or a cell population that can be used to create a therapeutic cell population “off-the-shelf” increases the availability and usefulness of new cellular therapies.B · US 2021/0123022 A1 · ¶ 6
patent.fyi, US 2026/0354359 A1, claim 1, first published 2026-11-18T21:55:14-05:00, https://patent.fyi/US20260354359/, SHA-256 3557effd592340db43b0ca09e4fe4dfdc4eee0e95bba44be779115c419dcf715